We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » After Delays, Avadel Gets Approval, Orphan Drug Exclusivity for Narcolepsy Drug
After Delays, Avadel Gets Approval, Orphan Drug Exclusivity for Narcolepsy Drug
After heated delays involving a competitor and the FDA, Dublin-based Avadel Pharmaceuticals has won FDA approval for Lumryz, its extended-release formulation of sodium oxybate for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy.